Axis-Shield signs deal with Abbott
Anglo-Norwegian firm Axis-Shield has signed an agreement with AbbottLaboratories, under which it will develop and manufacture a test for testosterone in human serum for the US major. The test will be exclusively marketed and distributed by Abbott worldwide.
The test will be developed by Axis-Shield for use on Abbott's AxSym system, which is described by the companies as "a leading automated immunoassay testing platform that combines continuous access, random access and STAT capabilities." It will be commercially launched worldwide in early 2003.
Nigel Keen, chairman and acting chief executive at Axis-Shield, said the deal "demonstrates how we work in partnership with global in vitro diagnostic suppliers to expand the menu of large-throughput laboratory systems." Furthermore, he added that teaming up with Abbott "provides us with additional validation of how our expertise in the rapid cost-effective development of assays for such systems is becoming increasingly recognized by large health care companies."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze